Envoy Chemical Technologies delivers a next-generation platform that integrates superparamagnetic iron-oxide nanoparticles (SPIONs) with precisely engineered drug conjugates to achieve field-guided, site-specific therapy.
Targeted Delivery– External magnetic fields steer our carrier–drug complexes through the vasculature, concentrating payloads within solid-tumour tissue while minimising off-target exposure.
On-Demand Activation – A proprietary radio-frequency (RF) applicator triggers controlled drug release and local hyperthermia, maximising cytotoxic effect inside the tumour micro-environment and sparing healthy cells.
Clinical Rigor – Syntheses, surface chemistries and conjugation protocols are developed under GMP-ready workflows, supported by full analytical characterisation (NMR, HPLC-MS, TEM, DLS).
Scalable Platform – Modular design enables rapid exchange of cytotoxic agents or biologics, creating a versatile pipeline of indications from oncology to precision immunology.
Safety & Compliance – Comprehensive pre-clinical studies address biodistribution, clearance and toxicology, aligning with EMA / FDA guidance for nanomedicine.
Envoy is redefining precision oncology by combining magnetism, molecular engineering and digital field control into a single, clinically actionable technology.
